Proteonomix commences UMK-121 study with patient screening
The University of Medicine & Dentistry of New Jersey together with the company screened the around 30 patients for the inclusion or exclusion in the study. Proteonomix chief
WellSpan Health and Johns Hopkins Medicine have renewed their oncology collaboration, aiming to widen patient access to advanced care, clinical expertise, and research initiatives throughout central Pennsylvania, US.
The primary endpoint of the placebo-controlled, multi-center study was achieved in 54% patients administered with pregabalin, compared to 70.7% patients in the placebo group. A statistically significant difference